This is a preview of subscription content, log in via an institution to check access.
Reference
Granström O, et al. Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension. ClinicoEconomics and Outcomes Research 4: 313-322, Nov 2012. Available from: URL: http://dx.doi.org/10.2147/CEOR.S35824
Additional information
* 2011 Swedish kronor
Rights and permissions
About this article
Cite this article
Candesartan dominates losartan in Sweden. PharmacoEconomics & Outcomes News 668, 4 (2012). https://doi.org/10.1007/s40274-012-0010-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-012-0010-1